

Publications about Reversing Type 2 Diabetes

(Most important in bold)

For a rapid general read, reference 56 gives an overview

1. **Taylor R. Pathogenesis of Type 2 Diabetes: Tracing the reverse path from cure to cause. *Diabetologia* 2008; 51:1781-1789. PMID: 18726585**
2. **Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: Normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. *Diabetologia* 2011; 54: 2506-2514. PMID 21656330**
3. Taylor R. Reversing the Twin Cycles of Type 2 Diabetes: The Banting Lecture 2012. *Diabetic Medicine* 2013; 267-275. PMID: 23075228 (IF 3.115)
4. Taylor R. Type 2 Diabetes: Etiology and Reversibility. *Diabetes Care*, April 2013; 36(4):1047-105; doi: 10.2337/dc12-1805. PMID: 23520370 (IF 11.9)
5. Steven S, Lim EL, Taylor R. Population response to information on reversibility of type 2 diabetes. *Diabet Med* 2013 Apr; 30(4):e135-8 doi: 10.1111/dme.12116. PMID: 23320491 (IF 3.115)
6. **Taylor R, Holman R. Normal weight individuals who develop type 2 diabetes: the personal fat threshold. *Clinical Science* 2015 Apr;128(7):405-410. doi: 10.1042/CS20140553 PMID: 25515001 (IF 5.598)**
7. Steven S, Carey PE, Small PK, Taylor R. Reversal of Type 2 diabetes after bariatric surgery is determined by the degree of achieved weight loss in both short- and longduration diabetes. *Diabet Med* 2015 Jan; 32(1):47-53. doi: 10.1111/dme.12567. Epub 2014 Sep 12. PMID: 25132043 (IF 3.115)
8. Steven S, Taylor, R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. *Diabet Med* 2015 32(9):1149-55. doi: 10.1111/dme.12722. PMID: 25683066 (IF 3.115)
9. Steven S, Hollingsworth KG, Small PK, Woodcock SA, Pucci A, Aribisala B AlMrabeh AA, Daly AK, Batterham RL, Taylor R. Weight loss decreases excess pancreatic triacylglycerol specifically in type 2 diabetes. *Diabetes Care* 2016 Jan;39(1):158-65. doi: 10.2337/dc15-0750. Epub 2015 Dec 1. PMID: 26628414 (IF 11.9)
10. Leslie WS, Ford I, Sattar N, Hollingsworth KG, Adamson A, Snihotta FF, McCombie L, Brosnahan N, Ross H, Mathers JC, Peters C, Thom G, Barnes A, Kean S, McIlvenna Y, Rodrigues A, Rehackova L, Zhyzhneuskaya S, Taylor R, Lean ME. The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial. *BMC Family Practice* 2016 Feb 16;17:20. doi:10.1186/s12875-016-0406-2.
11. <https://rdcu.be/6jwe> PMID: 26879684 (IF 1.67)
12. Rehackova L, Arnott B, Araujo-Soares V, Adamson AA, Taylor R, Snihotta FF. Efficacy and Acceptability of Very Low Energy Diets in Overweight and Obese People with Type 2 Diabetes Mellitus: A Systematic Review with Meta-analysis. *Diabetic Medicine* 2016; 33:580-9. doi 10.1111/dme.13005
13. White MG, Shaw JAM, Taylor R. Type 2 diabetes: The pathologic basis of reversible beta-cell dysfunction. *Diabetes Care* 2016; 39:2080-88. doi 10.2337/dc16-0619
14. **Steven S, Hollingsworth KG, Al-Mrabeh A, Avery L, Aribisala B, Caslake M, Taylor R. Very low-calorie diet and 6 months of weight stability in type 2 diabetes: Pathophysiologic changes in responders and nonresponders. *Diabetes Care* 2016 May 39(5):808-15. doi: 10.2337/dc15-1942. Epub ahead of print. PMID: 27002059 (IF 11.9)**
15. Steven S, Hollingsworth KG, Small PK, Woodcock SA, Pucci A, Aribisala B, AlMrabeh A, Batterham RL, Taylor R. Calorie restriction and not glucagon-like peptide1 explains the cute improvement in glucose control after gastric bypass in Type 2 diabetes. *Diabet Med* 2016 33:1723-31. doi: 10.1111/dme.13257. Epub ahead of print (IF 3.152)

16. Al-Mrabeh A, Hollingsworth KG, Steven S, Taylor R. Morphology of the pancreas in type 2 diabetes: effect of weight loss with or without normalisation of insulin secretory capacity. *Diabetologia* 2016 Aug; 59(8):1753-9. doi: 10.1007/s00125-016-3984-6. Epub 2016 May 14. PMID: 27179658; <https://rdcu.be/3K5G> (IF 6.671)
17. Al-Mrabeh A, Hollingsworth KG, Steven S, Tiniakos D and Taylor R. Quantification of intrapancreatic fat in type 2 diabetes by MRI. *PLOS One* 2017 Apr 3;12(4):e0174660. doi: 10.1371/journal.pone.0174660. PMID: 28369092 (IF 3.234)
18. Rehackova L, Araujo-Soares V, Adamson AJ, Steven S, Taylor R, Sniehotta F. F. Acceptability of a very-low-energy diet in Type 2 diabetes: patient experiences and behaviour regulation *Diabetic Med* 2017; 34: 1554–1567
19. Taylor R, Barnes A. Translating aetiological insight into sustainable management of type 2 diabetes? *Diabetologia* 2017; 61:273-83 doi: 10.1007/s00125-017-4504-z (IF 6.2)
20. Taylor R, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson2 AJ, Sniehotta FF, Mathers JM, Ross HM, McIlvenna Y, Stefanetti R, Trenell M, Welsh P, Kean S, Ford I, McConnachie A, Sattar N, Lean MEJ. Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohort. *Diabetologia* 2017; 61:589-98 <https://doi.org/10.1007/s00125-017-4503-0> (IF 6.2)
21. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson2 AJ, Sniehotta FF, Mathers JM, Ross HM, McIlvenna Y, Stefanetti R, Trenell M, Welsh P, Kean S, Ford I, McConnachie A, Sattar N, Taylor R. Primary care weight-management for type 2 diabetes: the clusterrandomised iabetes Remission Clinical Trial (DiRECT). *Lancet* 2017; 391:541-51 [doi.org/10.1016/S0140-6736\(17\)33102-1](https://doi.org/10.1016/S0140-6736(17)33102-1) (IF 44)
22. Taylor R, Barnes A. Can type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number one. *Diabetic Medicine* 2018; 00:1-8 (2018) doi: 10.1111/dme.13851
- 23. Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes A, Aribisala B, Hollingsworth KG, Mathers JC, Sattar N, Lean MEJ. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for beta cell recovery. *Cell Metab.* 2018 Oct 2;28(4):547-556.e3. doi: 10.1016/j.cmet.2018.07.003.**
24. Yiqiao X, Davies A, McCombie L, Briggs A, Messow C-M, Grieve E, Leslie WS, Taylor R, Lean MEJ. Within-trial cost and 1-year cost-effectiveness of the DiRECT/Counterweight-Plus weight-management programme to achieve remission of type 2 diabetes. *Lancet* 2018. doi:10.1016/S2213-8587(18)30346-2.
25. Taylor, R, Valabhji,J, Aveyard P, Paul,D. Prevention and reversal of Type 2 diabetes: highlights from a symposium at the 2019 Diabetes UK Annual Professional Conference. *Diabetic Medicine* 2018; 00:1-7 (2019) doi: 10.1111/dme.1389226. Taylor, R. Calorie restriction for long-term remission of type 2 diabetes. *Clinical Medicine* 2019 Vol 19, No 1:37-42
27. Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. *Lancet Diabetes and Endocrinology* 2019; 7:726-736
- 28. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JM, Ross HM, McIlvenna Y, Welsh, P, Kean, S, Ford I, McConnachie A, Messow, C-M Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet* 2019; 7: 344–55; doi:10.1016/s2213-8587(19)30068-3.**
29. Xin Y, Davies A, McCombie L, Briggs A, Messow C-M, Grieve E, Leslie WS, Taylor R, Lean MEJ. Type 2 diabetes remission: economic evaluation of the

- DiRECT/Counterweight-Plus weight management programme within a primary care randomized controlled trial. *Diabetic Medicine* 2019. doi:10.1111/dme.13981
30. Hopkins MD, Taylor R, Lean MEJ. The DiRECT principles: giving Type 2 diabetes remission programmes the best chance of success. *Diabetic Medicine* 2019. doi:10.111/dme.14126.
31. Taylor R, Barnes A. Can type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number one. *Diabetic Medicine* 2018; 00:1-8 (2018) doi: 10.1111/dme.13851
32. Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. *Lancet Diabetes and Endocrinology* 2019; 7:726-736
33. Taylor R. Calorie restriction for long-term remission of type 2 diabetes. *Clinical Medicine* 2019 Vol 19, No 1:37-42
34. Al-Mrabeh A; Zhyzhneuskaya SV; Peters C; Barnes AC; Melhem S; Jesuthasan A; Aribisala B; Hollingsworth KG; Liet G; Mather JC; Sattar N; Lean MEJ; Taylor R. Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss. *Cell Metabolism* 2019; doi:10.1016/j.cmet.2019.11.018
- 35. Zhyzhneuskaya SV, Al-Mrabeh A, Peters C, Barnes AC, Melhem S, Jesuthasan A, Aribisala B, Hollingsworth KG, McConnachie A, Sattar N, Lean MEJ, Taylor R. Time course of normalisation of functional beta cell capacity in DiRECT after weight loss in type 2 diabetes. *Diabetes Care* 2020; 43:813–820. <https://doi.org/10.2337/dc19-0371>**
36. Yiqiao X, Davies A, Briggs A, McCombie L, Messow C-M, Grieve E, Leslie WM, Taylor R, Lean MEJ. Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme. *Diabetologia* 2020; 63(10):2112-2122 DOI: 10.1007/s00125-020-05220-6;
37. Thom G, McIntosh A, Messow C-M, Leslie WS, Barnes A, Brosnahan N, McCombie L, Malkova D, Al-Mrabeh A, Zhyzhneuskaya S, Welsh P, Sattar N, Taylor R, Lean MEJ. Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT). *Diabetes Obes Metab* 2020; Dec 2; DOI: 10.1111/dom.14274
38. Al-Mrabeh A, Hollingsworth KG, Shaw JAM, McConnachie A, Sattar N; Lean MEJ, Taylor R. 2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol* 2020; 8: 939-948; doi: 10.1016/S2213-8587(20)30303-X
39. Al-Mrabeh A, Peters C, Hollingsworth KG, Taylor R. Measurement of intraorgan fat and hepatic output of triglycerides in human type 2 diabetes by magnetic resonance and intralipid infusion techniques. *Star Protocols* 2021; 2:1 <https://doi.org/10.1016/j.xpro.2021.100355>
40. Brosnahan N, Leslie W, McCombie L, Barnes A, Thom G, McConnachie A, Messow C M, Sattar N, Taylor R, Lean M E J. Brief formula low-energy-diet for relapse management during weight loss maintenance in the Diabetes Remission Clinical Trial (DiRECT). *J Hum Nutr Diet.* 2021;00:1-8 <https://doi.org/10.1111/jhn.12839>
41. Thom G, Messow C-M, Leslie WS, Barnes AC, Brosnahan N, McCombie EL, Al-Mrabeh A, Zhyzhneuskaya S, Welsh P, Sattar N, Taylor R, Lean MEJ. Predictors of type 2 diabetes remission in the Diabetes Remission Clinical Trial (DiRECT). *Diabetic Medicine* 2020 <https://doi.org/10.1111/dme.14395>
42. Shaden M, Steven S, Taylor R, Al-Mrabeh A. Effect of Weight Loss by Low-Calorie Diet on Cardiovascular Health in Type 2 Diabetes: An Interventional Cohort Study. *Nutrients* 2021, 13(5), 1465 doi: 10.3390/nu13051465
43. Rehackova L, Rodrigues AM, Thom G, Brosnahan N, Barnes AC, McCombie L, Leslie WS, Zhyzhneuskaya S, Peters C, Adamson AJ, Lean MEJ, Taylor R, Sniehotta FF. Participant experiences in the Diabetes REmission Clinical Trial (DiRECT). *Diabet Med* 2021;00:e14689 <https://doi.org/10.1111/dme.14689>
44. Leslie WS, Ali E, Harris L, Martina Messow C, Brosnahan NT, Thom G, McCombie EL,

- Barnes AC, Sattar N, Taylor R, Lean MEJ. Antihypertensive medication needs and blood pressure control with weight loss in the Diabetes REmission Clinical Trial (DiRECT). *Diabetologia* (2021) 64:1927–1938 <https://doi.org/10.1007/s00125-021-05471-x>
45. Jesuthasan A, Zhyzhneuskaya S, Peters C, Barnes AC, Hollingsworth KG, Sattar N, Lean MEJ, Taylor R, Al-Mrabeh AH. Sex differences in intraorgan fat levels and hepatic lipid metabolism: implications for cardiovascular health and remission of type 2 diabetes after dietary weight loss. *Diabetologia* 2022; 65(1): 226–233 <https://doi.org/10.1007/s00125-021-05583-4>
46. Rehackova L, Rodrigues AM, Thom G, Brosnahan N, Barnes AC, McCombie L, Leslie WS, Zhyzhneuskaya S, Peters C, Adamson AJ, Lean MEJ, Taylor R, Sniehotta FF. Delivering the Diabetes Remission Clinical Trial (DiRECT) in primary care: A mixed-methods study of experiences of health care. *Diabet Med* 2022 39:e14952; DOI: 10.1111/dme.14752
47. Williams SA, Rachel Ostroff, Michael A. Hinterberg, Josef Coresh, Christie M. Ballantyne, Matsushita K, Mueller CE, Walter J, Jonasson C, Holman RR, Shah SH, Sattar N, Taylor R, et al. A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. *Science Translational Reports* 2022, 14, eabj9625.
48. Cassidy S, Trenell M, Stefanetti RJ, Charman SJ, Barnes AC, Brosnahan N, McCombie L, Thom G, Peters C, Zhyzhneuskaya S, Leslie WS, Catt C, Catt M, McConnachie A, Sattar N, Sniehotta FF, Lean MEJ, Taylor R. Physical activity, inactivity and sleep during the Diabetes Remission Clinical Trial (DiRECT). *Diabetic Medicine* 2022 40:e15010. doi: 10.1111/dme.15010
49. Unwin D, Delon C, Unwin J, Tobin S, Taylor R. What predicts drug-free type 2 diabetes remission? Insights from an 8-year general practice service evaluation of a lower carbohydrate diet with weight loss *BMJ Nutrition, Prevention and Health* 2022 0:e000544. Doi:10.1136/bmjnph-2022-000544
50. Sattar N, Taheri S, Astling DP, Chadwick J, Hinterberg MA, Holmes MV, Troth EV, Welsh P, Zaghoul H, Chagoury O, Lean M, Taylor R, Williams S. Prediction of cardiometabolic health through changes in plasma proteins with intentional weight loss in the DiRECT and DIADEM-I randomised clinical trials of type 2 diabetes remission. *Diabetes Care* 2023; Sep 26:dc230602. doi: 10.2337/dc23-0602. Online ahead of print.
51. Corbin LJ, Hughes DA, Bull CJ, Vincent EE, Smith ML, McConnachie A, Messow C, Welsh P, Taylor R, Lean MEJ, Sattar N, Timpson NJ. The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT). *Diabetologia* 2023 Online
- 52. Taylor R, Barnes AC, Hollingsworth KG, Irvine KM, Solovyova A, Clark L, Martin-Ruiz C, Romeres R, Koulman A, Meek, CM, Jenkins B, Cobelli C, Holman R. Aetiology of Type 2 diabetes in people with a ‘normal’ body mass index: testing the personal fat threshold hypothesis. *Clin Sci (Lond)* (2023) 137: 1333–1346 doi.org/10.1042/CS20230586**
53. Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. *Lancet Diabetes and Endocrinol.* 2019; 7:726-736. doi: 10.1016/S2213-8587(19)30076-2
54. Taylor R. Type 2 diabetes and remission: practical management guided by pathophysiology. *Journal of Internal Medicine* 2021; 289: 754–770 <http://dx.doi.org/10.1111/joim.13214>
55. Taylor R. Remission of type 2 diabetes – Latest Information for Health care Professionals. *Practical Diabetes* 2020 37:177-182
56. Taylor R, Ramachandran A, Yancy Jr WS, Forouhi NG. Nutritional basis of type 2 diabetes remission. *Brit Med J* 2021; 373: n1449.
57. Petrov M, Taylor R. Intra-pancreatic fat deposition: Piecing the exocrine and endocrine pancreas together. *Nature Reviews Gastroenterology & Hepatology* 2021 online <https://doi.org/10.1038/s41575-021-00551-0>. [View

only <https://rdcu.be/cCQzO>]

58. Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, Rothberg AE, le Roux CW, Rubino F, Schauer P, Taylor R, Twenefour D Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

<https://doi.org/10.2337/dci21-0034>

59. Taylor R. Type 2 Diabetes: The Problem and the Solution. *Br J Diabetes*

2022;22(Suppl):S55-S58 <https://bjd-abcd.com/index.php/bjd/article/view/1055/1307>

60. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Kelly T, Irvine K, Peters C, Zhyzhneuskaya S, Hollingsworth KG, Adamson AA, Snihotta F, Mathers JC, McIlvenna Y, Welsh P, McConnachie A, McIntosh A, Sattar N, Taylor R. Five-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT): Extension study of continued support for weight loss maintenance. *Lancet Diabetes & Endocrinol.* 2024; 12:233-246

[https://doi.org/10.1016/S2213-8587\(23\)00385-6](https://doi.org/10.1016/S2213-8587(23)00385-6)

61. Valabhji J, Gorton Y, Barron E, Safazadeh S, Earnshaw F, Helm C, Virr M, Kernan J, Crowe S, Aveyard P, Wilding J, Willis T, Ells L, O'Neill S, Robertson E, Jebb S, Taylor R, Bakhai C. Early findings from the NHS Type 2 Diabetes Path to Remission Programme. *Lancet Diabetes and Endocrinology* 2024; 12:653-63. [https://doi.org/10.1016/S2213-8587\(24\)00194-3](https://doi.org/10.1016/S2213-8587(24)00194-3)

62. Zhyzhneuskaya SV, Al-Mrabeh A, Peters C, Barnes AC, Aribasala B, Hollingsworth KG, McConnachie A, Sattar N, Lean MEJ, **Taylor R.** Clinical utility of liver function tests for resolution of metabolic dysfunction-associated steatotic liver disease after weight loss in the Diabetes Remission Clinical Trial. *Diabetic Medicine* 2024 In press; published online: <https://doi.org/10.1111/dme.15462>